Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (32)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Barrett-Connor, E.
Right arrow Articles by Stuenkel, C. A
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barrett-Connor, E.
Right arrow Articles by Stuenkel, C. A
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Journal of Epidemiology 2001;30:423-426
© International Epidemiological Association 2001

Review

Hormone replacement therapy (HRT)— risks and benefits

Elizabeth Barrett-Connora and Cynthia A Stuenkelb

a Department of Family and Preventive Medicine and
b Department of Medicine, University of California, San Diego, School of Medicine, 9500 Gilman Drive, La Jolla, CA 92093–0607, USA. E-mail: ebarrettconnor@ucsd.edu

Despite 50 years of use, the first large randomized placebo-controlled clinical trials of postmenopausal hormone treatment and disease have only been reported in the last few years. These trials provided some surprising results, and raise questions about the short-term risk and long-term benefit of estrogen. Because clinical trials are the cornerstone of evidence-based medicine, this paper emphasizes clinical trial results whenever such are available.

Clinical trials have shown that estrogen therapy is very effective treatment for vasomotor symptoms (hot flushes and night sweats),1 which can begin several years before the last menstrual period when hormone levels are fluctuating.2 Clinical trials have also shown that estrogen can reduce vaginal dryness and urethritis, and that topical estrogen is at least as effective as systemic estrogen.3 The big questions about hormone therapy are not about short-term use for vasomotor symptoms or topical use for urogenital symptoms, but about long-term systemic use with its . . . [Full Text of this Article]

Osteoporosis

Coronary heart disease

Breast cancer

Endometrial cancer

Colon cancer

Memory loss and dementia

Venous thromboembolic disease

Conclusions

References


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Int J EpidemiolHome page
W. Maziak
The triumph of the null hypothesis: epidemiology in an age of change
Int. J. Epidemiol., April 1, 2009; 38(2): 393 - 402.
[Abstract] [Full Text] [PDF]

Home page
 J. Epidemiol. Community HealthHome page
N. Krieger, I. Lowy, R. Aronowitz, J. Bigby, K. Dickersin, E. Garner, J.-P. Gaudilliere, C. Hinestrosa, R. Hubbard, P. A Johnson, et al.
Hormone replacement therapy, cancer, controversies, and women's health: historical, epidemiological, biological, clinical, and advocacy perspectives
J Epidemiol Community Health, September 1, 2005; 59(9): 740 - 748.
[Abstract] [Full Text] [PDF]

Home page
 Arch NeurolHome page
S. W. J. Lamberts
The Endocrinology of Aging and the Brain
Arch Neurol, November 1, 2002; 59(11): 1709 - 1711.
[Full Text] [PDF]